Patients who met the primary endpoint at Month 6 had to have a first negative culture by Month 4.1,2
Culture conversion by Month 6 was a surrogate endpoint.1 Clinical benefit has not yet been established.
In the CONVERT trial, the endpoints of the change from baseline in 6MWT distance and SGRQ did not demonstrate clinical benefit at Month 6.1
aP<0.0001 vs standard therapy.